Aethlon Medical Inc., a San Diego-based medical device technology company focused on developing products to diagnose and treat life and organ threatening diseases, reported the closing of the previously announced underwritten public offering of 3,333,334 shares of common stock, and common warrants to purchase up to an aggregate of 3,333,334 shares of common stock at a public offering price of $1.50 per share.

Carlsbad, Calif.-based Chromacode Inc., a molecular diagnostics company, has secured $28 million in series C financing. The round was led by Northpond Ventures. Also participating were new investors Windham Ventures, Moore Venture Partners and the California Institute of Technology; and existing investors New Enterprise Associates, Domain Associates and Okapi Ventures.

Waltham, Mass.-based Eyegate Pharmaceuticals Inc. received about $1.9 million from the exercise of warrants subsequent to the release of positive topline data Nov. 22, for its pivotal corneal wound repair study.

Philadelphia-based Parvizi Surgical Innovation LLC made a minority investment in a development-stage hip replacement surgery device company Navbit Holdings Pty. Ltd., which is based in Sydney.

Walnut Creek, Calif.-based Trainer Rx, which focuses on musculoskeletal recovery, has secured $12 million in funding in a round led by Cigna Ventures. In addition, it has changed its name to Recoveryone.

Velano Vascular, of San Francisco, closed the second tranche of a $25 million growth financing that is earmarked for commercialization and the launch of additional novel inpatient medical device solutions. This new investment brings Velano’s total funding to more than $50 million from a mix of company insiders, venture capital firms, hospital partners and undisclosed health care industry multinationals.

No Comments